Novo Nordisk’s latest clinical trial for weight loss using CagriSema drug showed patients achieving 23% weight loss after 84 weeks. However, investors are not pleased, causing Novo Nordisk stock to drop 14.8%. The trial aimed to outperform Eli Lilly’s Zepbound and Mounjaro but fell short with CagriSema.

809 participants in the trial lost an average of 23% body weight with CagriSema, while Eli Lilly’s GLP-1 drug users lost 25.5%. Novo Nordisk plans to proceed with a higher-dose trial for CagriSema. However, the drug’s prospects are dimming, impacting investor expectations for a quick rebound.

Novo Nordisk had predicted a 5-13% decline in sales and earnings for 2026. Positive findings on CagriSema were hoped to boost the company, but now investors may need to wait longer for a rebound. Before investing in Novo Nordisk, consider the 10 best stocks identified by The Motley Fool Stock Advisor team, which doesn’t include Novo Nordisk.

Read more at Yahoo Finance: Why Novo Nordisk Stock Just Crashed